Issued Patents All Time
Showing 1–25 of 29 patents
| Patent # | Title | Co-Inventors | Date |
|---|---|---|---|
| 10912819 | Neuroprotective peptides derived from activity-dependent neuroprotective protein for treatment of neurological diseases | — | 2021-02-09 |
| 10822375 | Method for identifying a modulator of cell survival or plasticity | Saar Oz, Jacqueline Woang Cheing Tiong | 2020-11-03 |
| 10118943 | Compounds and methods for inhibiting cell death | Saar Oz, Jacqueline Woang Cheing Tiong | 2018-11-06 |
| 9518994 | Method for diagnosing and monitoring schizophrenia and tauopathies | Efrat Dresner | 2016-12-13 |
| 8618043 | Use of ADNF polypeptides for treating anxiety and depression | Roy N. Alcalay, Inna Divinski, Eliezer Giladi | 2013-12-31 |
| 8586548 | NAP alpha-aminoisobutyric acid analog with neuroprotective activity | — | 2013-11-19 |
| 8377875 | Therapeutics based on tau/microtubule dynamics | Maya Maor, Saar Oz, David Dangoor, Inna Divinski | 2013-02-19 |
| 8324166 | Neuroprotection using NAP-like and SAL-like peptide mimetics | Alistair James Stewart, Maya Maor, Sharon Furman-Assaf | 2012-12-04 |
| 8143221 | Use of ADNF polypeptides for treating peripheral neurotoxicity | James L. Miller | 2012-03-27 |
| 8067369 | Protection of the retina against laser injury by NAP and related peptides | Michael Belkin | 2011-11-29 |
| 8017578 | Orally active peptides that prevent cell damage and death | Douglas E. Brenneman, Catherine Y. Spong, Albert Pinhasov, Eliezer Giladi | 2011-09-13 |
| 7960334 | Use of ADNF III polypeptides for treating mental diseases and disorders, including schizophrenia | Roy N. Alcalay, Inna Divinski, Eliezer Giladi | 2011-06-14 |
| 7863247 | Prevention of fetal alcohol syndrome and neuronal cell death with ADNF polypeptides | Douglas E. Brenneman, Catherine Y. Spong, Merav Bassan, Rachel Zamostiano | 2011-01-04 |
| 7452867 | Use of ADNF polypeptides for treating peripheral neurotoxicity | James L. Miller | 2008-11-18 |
| 7427590 | Neurothrophic components of the ADNF I complex | Douglas E. Brenneman, Raquel Castellon, Catherine Y. Spong, Janet M. Hauser | 2008-09-23 |
| 7427598 | Post-natal administration of activity-dependent neurotrophic factor-derived polypeptides for enhancing learning and memory | Catherine Y. Spong, Douglas E. Brenneman | 2008-09-23 |
| 7384908 | Orally active peptides that prevent cell damage and death | Douglas E. Brenneman, Catherine Y. Spong, Albert Pinhasov, Eliezer Giladi | 2008-06-10 |
| 7264947 | Activity dependent neurotrophic factor III (ADNF III) | Douglas E. Brenneman, Merav Bassan, Rachel Zamostiano | 2007-09-04 |
| 6933277 | Prevention of fetal alcohol syndrome and neuronal cell death with ADNF polypeptides | Douglas E. Brenneman, Catherine Y. Spong, Merav Bassan, Rachel Zamostiano | 2005-08-23 |
| 6649411 | Methods of inhibiting cancer cells with ADNF III antisense oligonucleotides | Douglas E. Brenneman, Rachel Zamostiano, Edgar Gelber, Albert Pinhasov, Merav Bassan | 2003-11-18 |
| 6630124 | Combination therapy with VIP antagonist | Mati Fridkin, Edgar Gelber, Terry Moody, Douglas C. Brenneman | 2003-10-07 |
| 6613740 | Activity dependent neurotrophic factor III (ADNF III) | Douglas E. Brenneman, Merav Bassan, Rachel Zamostiano | 2003-09-02 |
| 6239107 | Conjugates of lipophilic moieties and fragments of vasoactive intestinal peptide (VIP) | Matityahu Fridkin | 2001-05-29 |
| 5998368 | Derivatives of structurally modified VIP and pharmaceutical compositions containing them | Matityahu Fridkin | 1999-12-07 |
| 5972883 | Method for the treatment of neurodegenerative diseases by administering VIP, an analogue, fragment or a conjugate thereof | Matityahu Fridkin | 1999-10-26 |